KAISA HEALTH (00876) announced its interim results for 2025, reporting revenue of HK$69.577 million, representing a 21.4% year-on-year decline. The loss attributable to equity holders was HK$9.125 million, narrowing by 62.4% compared to the previous year. Basic loss per share stood at HK$0.18 cents.

During the period, the revenue decrease was primarily attributed to the continued adverse impact of the Chinese government's centralized procurement pricing policies, including the establishment of price caps on dental products sold domestically, which led to reduced average selling prices for dental products.

The Group's research and development direction has consistently adhered to the aesthetic restoration philosophy of "minimally invasive dental care," allowing patients to experience reduced discomfort and achieve aesthetic improvements with ease. In 2019, the company's subsidiary brands launched a series of digitalized dental products including Meijia Veneer XS, Meijia 3D Simulated Zirconia, Meijia Easy-Align Clear Aligners, and removable dentures, which have received significant recognition from overseas technicians and dentists.

To provide better and faster products and services, the company plans to establish regional manufacturing centers in Shanghai and Chengdu this year to reduce logistics costs and further serve local customers.

As of June 2025, all Hejia rehabilitation clinics successfully met the periodic performance assessments conducted by Shenzhen Medical Insurance Bureau for designated medical insurance institutions, smoothly entering contract renewals. Across the city, 2%-5% of institutions lost their designated medical insurance institution qualifications due to failing the assessments. Hejia rehabilitation clinics expanded their teams in the first half of the year, with operating revenue increasing 15% year-on-year.